Tag: list

ROCKVILLE, Md. and SUZHOU, China, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that it has received clearance by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to conduct GLORA-4 study (NCT06641414), a global registrational Phase III study of lisaftoclax (APG-2575), a proprietary Bcl-2 inhibitor, in combination with azacitidine (AZA), for the treatment of patients with newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS).

Public curiosity around nerve health is rising in 2025, with searches, podcasts, and social platforms highlighting natural approaches. Nerve Soothe enters this conversation with a formula designed around ingredient transparency, plant-based extracts, and consumer-driven expectations for wellness support.

An In-Depth 2025 Analysis of PurelyWHITE Deluxe Teeth Whitening Powder and Consumer Trends in Sensitivity-Free Oral Care

Oslo, Norway (15 August 2025) – TGS has issued awards of Performance Share Units (PSUs) and Restricted Share Units (RSUs) to 283 key employees of the Company, as authorized by the shareholders of the company at its Annual General Meeting on 8 May 2025.  With the exception of certain PSUs and RSUs, which may be secured by the Company’s treasury stock, the PSUs and RSUs are secured by free-standing warrants that, upon vesting of the PSUs and RSUs in accordance with their terms, are convertible to shares of the Company’s common stock.  Each PSU represents the right to receive a maximum of 1.5 shares, while each RSU represents the right to receive one share.